THE SHARE: Change: -0.01 SEK (-2.43%) / Price: 0.28 SEK / Jul 9, 2025, 5:29 pm (CEST)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

MAR

  • 1 Oct, 2024
    Spago Nanomedical i ny fas med fullt fokus på Tumorad-programmet
  • 1 Oct, 2024
    Spago Nanomedical in new phase with full focus on the Tumorad program
  • 15 Dec, 2023
    Spago Nanomedical rapporterar positiva topline-data från den kliniska fas 2a studien SPAGOPIX-02 i patienter med endometrios
  • 15 Dec, 2023
    Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis
  • 7 Dec, 2023
    Första patienten doserad i Spago Nanomedicals kliniska fas I/IIa-studie inom Tumorad®-programmet
  • 7 Dec, 2023
    First patient dosed in Spago Nanomedical’s clinical phase I/IIa study within the Tumorad® program
  • 19 Oct, 2023
    Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien
  • 19 Oct, 2023
    Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia
  • 5 Oct, 2023
    Spago Nanomedical föreslår en fullt garanterad företrädesemission av units om cirka 30,6 MSEK för att avancera Tumorad
  • 5 Oct, 2023
    Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad
  • 1
  • 2
  • 3
  • …
  • 9
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2025 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications